Identification

Name
Minaprine
Accession Number
DB00805  (APRD00735)
Type
Small Molecule
Groups
Approved
Description

Minaprine is a psychotropic drug which has proved to be effective in the treatment of various depressive states. Like most antidepressants minaprine antagonizes behavioral despair. Minaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain.

Structure
Thumb
Synonyms
  • 4-(2-((4-Methyl-6-phenyl-3-pyridazinyl)amino)ethyl)morpholine
  • 4-Methyl-3-(2-morpholinoethylamino)-6-phenylpyridazin
  • Minaprina
  • Minaprinum
  • N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine
Product Ingredients
IngredientUNIICASInChI Key
Minaprine Dihydrochloride82Y7NT6DFT25953-17-7GNUCGROXDZMCJI-UHFFFAOYSA-N
International/Other Brands
Cantor (Sanofi-Aventis)
Categories
UNII
00U7GX0NLM
CAS number
25905-77-5
Weight
Average: 298.3828
Monoisotopic: 298.179361346
Chemical Formula
C17H22N4O
InChI Key
LDMWSLGGVTVJPG-UHFFFAOYSA-N
InChI
InChI=1S/C17H22N4O/c1-14-13-16(15-5-3-2-4-6-15)19-20-17(14)18-7-8-21-9-11-22-12-10-21/h2-6,13H,7-12H2,1H3,(H,18,20)
IUPAC Name
4-methyl-N-[2-(morpholin-4-yl)ethyl]-6-phenylpyridazin-3-amine
SMILES
CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of depression

Structured Indications
Not Available
Pharmacodynamics

Minaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain. Similar to other antidepressant treatments, minaprine attenuates the beta-adrenergic receptor function. Studies have also shown that minaprine improves memory consolidation and that repeated drug administration leads to potentiation of this effect. Moreover, the effects of minaprine on memory consolidation are related to its dopaminergic action.

Mechanism of action

Minaprine binds to serotonin type 2 receptors and to dopamine D1 and D2 type receptors. It also binds to the serotonin reuptake pump. Therefore, minaprine blocks the reuptake of both dopamine and serotonin. It is also, to a slight degree, cholinomimetic. Thus it may exhibit both mood-brightening and nootropic properties. It also acts as a reversible inhibitor of MAO-A (RIMA).It has also been found to inhibit acetylcholinesterase.

TargetActionsOrganism
AAmine oxidase [flavin-containing] A
inhibitor
Human
A5-hydroxytryptamine receptor 2B
antagonist
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
A5-hydroxytryptamine receptor 2C
antagonist
Human
AAcetylcholinesterase
inhibitor
Human
USodium-dependent serotonin transporter
inhibitor
Human
UD(1A) dopamine receptor
agonist
Human
UD(2) dopamine receptor
agonist
Human
UMuscarinic acetylcholine receptor M1
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic. Cytochrome P4502D is responsible for the 4-hydroxylation of minaprine to 4-hydroxyminaprine.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Minaprine.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Minaprine.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamineMinaprine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineMinaprine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineMinaprine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Minaprine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineMinaprine may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbirateroneThe serum concentration of Minaprine can be increased when it is combined with Abiraterone.Approved
AcarboseMinaprine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololMinaprine may increase the bradycardic activities of Acebutolol.Approved
AcetylcholineThe risk or severity of adverse effects can be increased when Minaprine is combined with Acetylcholine.Approved
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Minaprine.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Minaprine.Experimental
AlbiglutideMinaprine may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Minaprine.Approved
AlcuroniumThe therapeutic efficacy of Alcuronium can be decreased when used in combination with Minaprine.Experimental
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Minaprine.Experimental, Investigational
AlfentanilAlfentanil may increase the serotonergic activities of Minaprine.Approved, Illicit
AliskirenMinaprine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Minaprine.Approved, Investigational
AlogliptinMinaprine may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Minaprine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Minaprine.Illicit
AlprenololMinaprine may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Minaprine.Approved
AmbrisentanMinaprine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Minaprine.Approved
AmineptineMinaprine may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmiodaroneThe metabolism of Minaprine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineMinaprine may increase the serotonergic activities of Amitriptyline.Approved
AmlodipineMinaprine may increase the hypotensive activities of Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Minaprine is combined with Amoxapine.Approved
AmphetamineMinaprine may increase the hypertensive activities of Amphetamine.Approved, Illicit
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Minaprine.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Minaprine.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Minaprine.Investigational
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Minaprine.Approved
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Minaprine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Minaprine is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Minaprine is combined with Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Minaprine is combined with Arecoline.Experimental
ArformoterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Arformoterol.Approved, Investigational
ArotinololMinaprine may increase the bradycardic activities of Arotinolol.Approved, Investigational
ArtemetherThe metabolism of Minaprine can be decreased when combined with Artemether.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Minaprine.Investigational
AtenololMinaprine may increase the bradycardic activities of Atenolol.Approved
AtomoxetineMinaprine may increase the central neurotoxic activities of Atomoxetine.Approved
AtracuriumThe therapeutic efficacy of Atracurium can be decreased when used in combination with Minaprine.Experimental, Investigational
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Minaprine.Approved
AtropineMinaprine may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Bambuterol.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Minaprine.Approved, Investigational
BefunololMinaprine may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Minaprine.Withdrawn
BenazeprilMinaprine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideMinaprine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinMinaprine may increase the hypertensive activities of Benmoxin.Withdrawn
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Minaprine.Approved
BenzphetamineMinaprine may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilMinaprine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Minaprine.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Minaprine.Approved, Vet Approved
BetaxololMinaprine may increase the bradycardic activities of Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Minaprine is combined with Bethanechol.Approved
BethanidineMinaprine may increase the hypotensive activities of Bethanidine.Approved
BevantololMinaprine may increase the bradycardic activities of Bevantolol.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Minaprine is combined with Bezafibrate.Approved
BietaserpineMinaprine may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostMinaprine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Minaprine.Approved, Investigational
BisoprololMinaprine may increase the bradycardic activities of Bisoprolol.Approved
BopindololMinaprine may increase the bradycardic activities of Bopindolol.Approved
BornaprineThe therapeutic efficacy of Bornaprine can be decreased when used in combination with Minaprine.Experimental
BosentanMinaprine may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Minaprine may increase the hypotensive activities of BQ-123.Investigational
BretyliumMinaprine may increase the hypotensive activities of Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Minaprine is combined with Brimonidine.Approved
BrofaromineMinaprine may increase the hypertensive activities of Brofaromine.Experimental
BromocriptineMinaprine may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucindololMinaprine may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Minaprine.Approved
BufuralolMinaprine may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BupranololMinaprine may increase the bradycardic activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Minaprine.Approved, Illicit, Investigational, Vet Approved
BupropionMinaprine may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Minaprine.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Minaprine.Approved, Illicit, Vet Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Minaprine.Approved
CadralazineMinaprine may increase the hypotensive activities of Cadralazine.Experimental
CafedrineMinaprine may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinMinaprine may increase the hypoglycemic activities of Canagliflozin.Approved
Candesartan cilexetilMinaprine may increase the hypotensive activities of Candesartan.Approved
CandoxatrilMinaprine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilMinaprine may increase the hypotensive activities of Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Minaprine is combined with Carbachol.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Minaprine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Minaprine.Illicit, Investigational, Vet Approved
CaroxazoneMinaprine may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololMinaprine may increase the bradycardic activities of Carteolol.Approved
CarvedilolMinaprine may increase the bradycardic activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Minaprine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololMinaprine may increase the bradycardic activities of Celiprolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Minaprine is combined with Cevimeline.Approved
ChloroquineThe metabolism of Minaprine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideMinaprine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Minaprine.Withdrawn
ChlorphentermineMinaprine may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Minaprine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideMinaprine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneMinaprine may increase the hypotensive activities of Chlorthalidone.Approved
CholecalciferolThe metabolism of Minaprine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Minaprine.Approved, Investigational
CicletanineMinaprine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilMinaprine may increase the hypotensive activities of Cilazapril.Approved
CimetidineThe metabolism of Minaprine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Minaprine can be decreased when combined with Cinacalcet.Approved
CirazolineMinaprine may increase the hypertensive activities of Cirazoline.Experimental
CitalopramThe metabolism of Minaprine can be decreased when combined with Citalopram.Approved
ClemastineMinaprine may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClobazamThe metabolism of Minaprine can be decreased when combined with Clobazam.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Minaprine.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Minaprine.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Minaprine.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Minaprine.Approved
ClomipramineThe metabolism of Minaprine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineMinaprine may increase the hypotensive activities of Clonidine.Approved
CloranololMinaprine may increase the bradycardic activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Minaprine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Minaprine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Minaprine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Minaprine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Minaprine.Approved, Illicit
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Minaprine.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Minaprine.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Minaprine.Approved
CryptenamineMinaprine may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Minaprine.Approved
CyclopenthiazideMinaprine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Minaprine.Approved
CyclothiazideMinaprine may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineMinaprine may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinMinaprine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineMinaprine may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Minaprine.Approved, Investigational
DarunavirThe serum concentration of Minaprine can be increased when it is combined with Darunavir.Approved
DebrisoquinMinaprine may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilMinaprine may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Minaprine can be decreased when combined with Delavirdine.Approved
DeserpidineMinaprine may increase the hypotensive activities of Deserpidine.Approved
DesipramineThe metabolism of Minaprine can be decreased when combined with Desipramine.Approved
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Minaprine.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Minaprine.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Minaprine.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Minaprine.Experimental, Vet Approved
DesvenlafaxineMinaprine may increase the serotonergic activities of Desvenlafaxine.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Minaprine.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Minaprine.Vet Approved
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Minaprine.Withdrawn
DexmethylphenidateMinaprine may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetamineMinaprine may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanMinaprine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Minaprine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Minaprine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Minaprine.Approved, Investigational
DiazoxideMinaprine may increase the hypotensive activities of Diazoxide.Approved
DibenzepinMinaprine may increase the serotonergic activities of Dibenzepin.Experimental
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Minaprine.Approved
diethylnorspermineMinaprine may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylpropionMinaprine may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Minaprine.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Minaprine.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Minaprine.Approved
DihydralazineMinaprine may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Minaprine.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Minaprine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Minaprine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Minaprine.Experimental, Illicit
DiltiazemMinaprine may increase the hypotensive activities of Diltiazem.Approved
DiphenhydramineThe metabolism of Minaprine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Minaprine.Approved, Illicit
DipivefrinThe risk or severity of adverse effects can be increased when Minaprine is combined with Dipivefrin.Approved
DipyridamoleThe therapeutic efficacy of Minaprine can be decreased when used in combination with Dipyridamole.Approved
DisopyramideMinaprine may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Minaprine is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Minaprine is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideMinaprine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe metabolism of Minaprine can be decreased when combined with Dosulepin.Approved
DoxapramMinaprine may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinMinaprine may increase the hypotensive activities of Doxazosin.Approved
DoxepinMinaprine may increase the serotonergic activities of Doxepin.Approved
DoxylamineMinaprine may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Minaprine.Investigational
DronedaroneThe metabolism of Minaprine can be decreased when combined with Dronedarone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Minaprine.Experimental, Illicit
DroxidopaThe risk or severity of adverse effects can be increased when Minaprine is combined with Droxidopa.Approved, Investigational
DulaglutideMinaprine may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineThe metabolism of Minaprine can be decreased when combined with Duloxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Minaprine.Experimental, Illicit
EfonidipineMinaprine may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Minaprine.Approved, Investigational
EliglustatThe metabolism of Minaprine can be decreased when combined with Eliglustat.Approved
EmeproniumThe therapeutic efficacy of Emepronium can be decreased when used in combination with Minaprine.Experimental
EmpagliflozinMinaprine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilMinaprine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatMinaprine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineMinaprine may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Minaprine.Approved, Investigational
EpanololMinaprine may increase the bradycardic activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Minaprine is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Minaprine is combined with Epibatidine.Experimental
EpoprostenolMinaprine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanMinaprine may increase the hypotensive activities of Eprosartan.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Minaprine.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Minaprine.Approved
ErgotamineMinaprine may increase the hypertensive activities of Ergotamine.Approved
EscitalopramMinaprine may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmirtazapineMinaprine may increase the serotonergic activities of Esmirtazapine.Investigational
EsmololMinaprine may increase the bradycardic activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Minaprine.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Minaprine.Approved
EtanautineThe therapeutic efficacy of Etanautine can be decreased when used in combination with Minaprine.Experimental
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Minaprine.Approved
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Minaprine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Minaprine.Approved, Illicit
EtoperidoneMinaprine may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Minaprine.Illicit, Vet Approved
EtybenzatropineThe therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Minaprine.Experimental
ExenatideMinaprine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineMinaprine may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineThe risk or severity of adverse effects can be increased when Minaprine is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FenoldopamMinaprine may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Fenoterol.Approved, Investigational
FentanylFentanyl may increase the serotonergic activities of Minaprine.Approved, Illicit, Investigational, Vet Approved
Ferulic acidMinaprine may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Minaprine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Minaprine.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Minaprine.Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Minaprine.Approved, Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Minaprine.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Minaprine.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Minaprine.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Minaprine.Approved
FluoxetineThe metabolism of Minaprine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Minaprine.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Minaprine.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Minaprine.Approved
FluvoxamineThe metabolism of Minaprine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Minaprine.Approved, Investigational, Withdrawn
FormoterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Formoterol.Approved, Investigational
FosinoprilMinaprine may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Minaprine.Approved, Investigational
FurazolidoneMinaprine may increase the hypertensive activities of Furazolidone.Approved, Investigational, Vet Approved
GallamineThe therapeutic efficacy of Gallamine can be decreased when used in combination with Minaprine.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Minaprine.Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Minaprine.Experimental
GliclazideMinaprine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideMinaprine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideMinaprine may increase the hypoglycemic activities of Glipizide.Approved
GlyburideMinaprine may increase the hypoglycemic activities of Glyburide.Approved
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Minaprine.Approved, Investigational, Vet Approved
GTS-21The risk or severity of adverse effects can be increased when Minaprine is combined with GTS-21.Investigational
GuanabenzMinaprine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelMinaprine may increase the hypotensive activities of Guanadrel.Approved
GuanazodineMinaprine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineMinaprine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineMinaprine may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorMinaprine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzMinaprine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanMinaprine may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe metabolism of Minaprine can be decreased when combined with Haloperidol.Approved
HarmalineMinaprine may increase the hypertensive activities of Harmaline.Experimental
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Minaprine.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Minaprine.Approved, Illicit, Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Minaprine.Experimental
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Minaprine.Approved
HydracarbazineMinaprine may increase the hypertensive activities of Hydracarbazine.Experimental
HydralazineMinaprine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideMinaprine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Minaprine is combined with Hydrocodone.Approved, Illicit
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Minaprine.Approved, Vet Approved
HydroflumethiazideMinaprine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Minaprine is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineMinaprine may increase the hypertensive activities of Hydroxyamphetamine.Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Minaprine.Approved
ImidaprilMinaprine may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe metabolism of Minaprine can be decreased when combined with Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Indacaterol.Approved
IndalpineMinaprine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideMinaprine may increase the hypotensive activities of Indapamide.Approved
IndenololMinaprine may increase the bradycardic activities of Indenolol.Withdrawn
IndinavirThe metabolism of Minaprine can be decreased when combined with Indinavir.Approved
IndoraminMinaprine may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartMinaprine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirMinaprine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineMinaprine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineMinaprine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanMinaprine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproMinaprine may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Minaprine.Approved
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Minaprine.Approved
IprindoleMinaprine may increase the serotonergic activities of Iprindole.Experimental
IproclozideMinaprine may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidMinaprine may increase the hypertensive activities of Iproniazid.Withdrawn
IrbesartanMinaprine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidMinaprine may increase the hypertensive activities of Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Minaprine is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Minaprine is combined with Isometheptene.Approved
IsoniazidThe metabolism of Minaprine can be decreased when combined with Isoniazid.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Minaprine is combined with Isoprenaline.Approved
IsradipineMinaprine may increase the hypotensive activities of Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Minaprine.Investigational
KetanserinMinaprine may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Minaprine.Approved, Investigational
KetoconazoleThe metabolism of Minaprine can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Minaprine.Approved, Nutraceutical, Withdrawn
LabetalolMinaprine may increase the bradycardic activities of Labetalol.Approved
LacidipineMinaprine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LandiololMinaprine may increase the bradycardic activities of Landiolol.Investigational
LatanoprostMinaprine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineMinaprine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololMinaprine may increase the bradycardic activities of Levobunolol.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Minaprine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Minaprine.Approved, Investigational
LevomilnacipranMinaprine may increase the serotonergic activities of Levomilnacipran.Approved
LevonordefrinMinaprine may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Minaprine.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Minaprine is combined with Levosalbutamol.Approved
LinezolidThe risk or severity of adverse effects can be increased when Minaprine is combined with Linezolid.Approved, Investigational
LinsidomineMinaprine may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideMinaprine may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineMinaprine may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilMinaprine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Minaprine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Minaprine is combined with Lithium.Approved
LobelineThe risk or severity of adverse effects can be increased when Minaprine is combined with Lobeline.Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Minaprine.Illicit
LofepramineMinaprine may increase the serotonergic activities of Lofepramine.Experimental
LofexidineMinaprine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Minaprine can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Minaprine can be decreased when combined with Lorcaserin.Approved
LosartanMinaprine may increase the hypotensive activities of Losartan.Approved
LumefantrineThe metabolism of Minaprine can be decreased when combined with Lumefantrine.Approved
MacitentanMinaprine may increase the hypotensive activities of Macitentan.Approved
ManidipineMinaprine may increase the hypotensive activities of Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Minaprine.Approved
MazaticolThe therapeutic efficacy of Mazaticol can be decreased when used in combination with Minaprine.Experimental
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Minaprine.Investigational
MebanazineMinaprine may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Minaprine.Approved
MecaserminMinaprine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Minaprine.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Minaprine.Vet Approved
MephedroneMinaprine may increase the hypertensive activities of Mephedrone.Investigational
MephentermineMinaprine may increase the hypertensive activities of Mephentermine.Approved
MepindololMinaprine may increase the bradycardic activities of Mepindolol.Experimental
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Minaprine.Experimental
MequitazineMinaprine may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolMinaprine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminMinaprine may increase the hypoglycemic activities of Metformin.Approved
MethacholineThe risk or severity of adverse effects can be increased when Minaprine is combined with Methacholine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Minaprine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Minaprine.Approved, Illicit
MethamphetamineMinaprine may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Minaprine.Approved, Investigational
MethoserpidineMinaprine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe metabolism of Minaprine can be decreased when combined with Methotrimeprazine.Approved
MethoxamineMinaprine may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Minaprine.Experimental
MethyldopaThe risk or severity of adverse effects can be increased when Minaprine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Minaprine.Experimental
Methylene blueMinaprine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateMinaprine may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Minaprine.Approved, Vet Approved
MetipranololMinaprine may increase the hypotensive activities of Metipranolol.Approved
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Minaprine.Approved
MetolazoneMinaprine may increase the hypotensive activities of Metolazone.Approved
MetoprololMinaprine may increase the bradycardic activities of Metoprolol.Approved, Investigational
MetyrosineMinaprine may increase the hypotensive activities of Metyrosine.Approved
MianserinMinaprine may increase the neurotoxic activities of Mianserin.Approved, Investigational
MibefradilMinaprine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineMinaprine may increase the hypertensive activities of Midodrine.Approved
MidomafetamineMinaprine may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Minaprine can be decreased when combined with Midostaurin.Approved
MifepristoneMinaprine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolMinaprine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranMinaprine may increase the serotonergic activities of Milnacipran.Approved
MinoxidilMinaprine may increase the hypotensive activities of Minoxidil.Approved
MirabegronThe metabolism of Minaprine can be decreased when combined with Mirabegron.Approved
MirtazapineMinaprine may increase the central neurotoxic activities of Mirtazapine.Approved
MivacuriumMinaprine may decrease the neuromuscular blocking activities of Mivacurium.Approved
MMDAMinaprine may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Minaprine is combined with Moclobemide.Approved
MoexiprilMinaprine may increase the hypotensive activities of Moexipril.Approved
MoxonidineMinaprine may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineMinaprine may increase the hypotensive activities of Muzolimine.Experimental
NadololMinaprine may increase the bradycardic activities of Nadolol.Approved
NaftopidilMinaprine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Minaprine.Approved
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Minaprine.Approved, Investigational
NateglinideMinaprine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Minaprine.Investigational
NebivololMinaprine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneMinaprine may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NevirapineThe metabolism of Minaprine can be decreased when combined with Nevirapine.Approved
NialamideMinaprine may increase the hypertensive activities of Nialamide.Withdrawn
NicardipineThe metabolism of Minaprine can be decreased when combined with Nicardipine.Approved
NicorandilMinaprine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Minaprine is combined with Nicotine.Approved
NiguldipineMinaprine may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Minaprine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineMinaprine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineMinaprine may increase the hypotensive activities of Nimodipine.Approved
NisoldipineMinaprine may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineMinaprine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideMinaprine may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrineMinaprine may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Minaprine.Approved, Illicit
NortriptylineMinaprine may increase the serotonergic activities of Nortriptyline.Approved
OctamoxinMinaprine may increase the hypertensive activities of Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Minaprine is combined with Olanzapine.Approved, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Minaprine.Investigational
OlmesartanMinaprine may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Olodaterol.Approved
OmapatrilatMinaprine may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolMinaprine may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Minaprine.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Minaprine is combined with Orciprenaline.Approved
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Minaprine.Approved
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Minaprine.Experimental, Investigational
OxitropiumThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Minaprine.Investigational
OxprenololMinaprine may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Minaprine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Minaprine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Minaprine.Approved, Investigational, Vet Approved
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Minaprine.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Minaprine.Approved
PanobinostatThe serum concentration of Minaprine can be increased when it is combined with Panobinostat.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Minaprine.Approved
PargylineMinaprine may increase the hypotensive activities of Pargyline.Approved
ParoxetineThe metabolism of Minaprine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Minaprine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololMinaprine may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentamidineMinaprine may increase the hypoglycemic activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Minaprine.Approved, Vet Approved
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Minaprine.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Minaprine.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilMinaprine may increase the hypotensive activities of Perindopril.Approved
PethidineMinaprine may increase the serotonergic activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Minaprine.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Minaprine.Approved
PhenglutarimideThe therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Minaprine.Experimental
PheniprazineMinaprine may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Minaprine.Experimental
PhenoxybenzamineMinaprine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineMinaprine may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineMinaprine may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolamineMinaprine may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineMinaprine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Minaprine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Minaprine.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Minaprine.Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Minaprine is combined with Pilocarpine.Approved
PinacidilMinaprine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololMinaprine may increase the bradycardic activities of Pindolol.Approved
PioglitazoneMinaprine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Minaprine.Approved
PirbuterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Pirbuterol.Approved
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Minaprine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Minaprine.Investigational
PirlindoleMinaprine may increase the hypertensive activities of Pirlindole.Approved
PivhydrazineMinaprine may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenMinaprine may increase the anticholinergic activities of Pizotifen.Approved
PolythiazideMinaprine may increase the hypotensive activities of Polythiazide.Approved
PractololMinaprine may increase the bradycardic activities of Practolol.Approved
PramlintideMinaprine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Minaprine.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Minaprine.Investigational
PrazosinMinaprine may increase the hypotensive activities of Prazosin.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Minaprine.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Minaprine.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Minaprine.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Minaprine.Experimental, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Procaterol.Approved, Investigational
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Minaprine.Approved
PromazineThe metabolism of Minaprine can be decreased when combined with Promazine.Approved, Vet Approved
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Minaprine.Approved
PropiverineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Minaprine.Approved, Investigational
PropranololMinaprine may increase the bradycardic activities of Propranolol.Approved, Investigational
ProtriptylineMinaprine may increase the serotonergic activities of Protriptyline.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Minaprine.Investigational
PseudoephedrineMinaprine may increase the hypertensive activities of Pseudoephedrine.Approved
QuinaprilMinaprine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineThe metabolism of Minaprine can be decreased when combined with Quinidine.Approved
QuinineMinaprine may increase the hypoglycemic activities of Quinine.Approved
RamiprilMinaprine may increase the hypotensive activities of Ramipril.Approved
RanolazineThe metabolism of Minaprine can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumMinaprine may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineMinaprine may increase the hypertensive activities of Rasagiline.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Minaprine.Approved
RemikirenMinaprine may increase the hypotensive activities of Remikiren.Approved
RepaglinideMinaprine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineMinaprine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Minaprine is combined with Reserpine.Approved, Investigational
RilmenidineMinaprine may increase the hypotensive activities of Rilmenidine.Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Minaprine.Approved
RiociguatMinaprine may increase the hypotensive activities of Riociguat.Approved
RitobegronMinaprine may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Minaprine is combined with Ritodrine.Approved, Investigational
RitonavirThe metabolism of Minaprine can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Minaprine.Approved
RolapitantThe metabolism of Minaprine can be decreased when combined with Rolapitant.Approved
RosiglitazoneMinaprine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SafrazineMinaprine may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Minaprine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Salmeterol.Approved
SaprisartanMinaprine may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinMinaprine may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Minaprine.Approved
Scopolamine butylbromideThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Minaprine.Approved, Vet Approved
SelegilineMinaprine may increase the hypertensive activities of Selegiline.Approved, Investigational, Vet Approved
SelexipagMinaprine may increase the hypotensive activities of Selexipag.Approved
SertralineThe metabolism of Minaprine can be decreased when combined with Sertraline.Approved
SitagliptinMinaprine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanMinaprine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Minaprine.Approved
SotalolMinaprine may increase the bradycardic activities of Sotalol.Approved
SpiraprilMinaprine may increase the hypotensive activities of Spirapril.Approved
StiripentolThe metabolism of Minaprine can be decreased when combined with Stiripentol.Approved
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Minaprine.Approved
SufentanilSufentanil may increase the serotonergic activities of Minaprine.Approved, Investigational
SulfadiazineMinaprine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleMinaprine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleMinaprine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Minaprine.Approved, Investigational
SunitinibMinaprine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololMinaprine may increase the bradycardic activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Minaprine.Approved
TelmisartanMinaprine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilMinaprine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbinafineThe metabolism of Minaprine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Minaprine is combined with Terbutaline.Approved
TerlipressinMinaprine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TertatololMinaprine may increase the bradycardic activities of Tertatolol.Experimental
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Minaprine.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Minaprine.Approved
TetrahydropalmatineMinaprine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineMinaprine may increase the hypertensive activities of Tetryzoline.Approved
TheodrenalineMinaprine may increase the hypotensive activities of Theodrenaline.Investigational
ThioridazineThe metabolism of Minaprine can be decreased when combined with Thioridazine.Approved, Withdrawn
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Minaprine.Approved, Investigational
TiboloneMinaprine may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Minaprine can be decreased when combined with Ticlopidine.Approved
TicrynafenMinaprine may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Minaprine.Experimental
TimololMinaprine may increase the bradycardic activities of Timolol.Approved
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Minaprine.Approved
TipranavirThe metabolism of Minaprine can be decreased when combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Minaprine.Approved
TolazamideMinaprine may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineMinaprine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideMinaprine may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Minaprine.Approved, Withdrawn
TolonidineMinaprine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneMinaprine may increase the hypertensive activities of Toloxatone.Approved
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Minaprine.Approved, Investigational
TorasemideMinaprine may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Minaprine.Approved, Investigational
TrandolaprilMinaprine may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineMinaprine may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Minaprine can be decreased when combined with Tranylcypromine.Approved
TravoprostMinaprine may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Minaprine is combined with Trazodone.Approved, Investigational
TreprostinilMinaprine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Minaprine.Approved, Vet Approved
TrichlormethiazideMinaprine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Minaprine.Approved
TrimazosinMinaprine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Minaprine.Approved, Investigational
TrimipramineMinaprine may increase the serotonergic activities of Trimipramine.Approved
TropatepineThe therapeutic efficacy of Tropatepine can be decreased when used in combination with Minaprine.Experimental
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Minaprine.Approved
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Minaprine.Approved
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Minaprine.Approved
UnoprostoneMinaprine may increase the hypotensive activities of Unoprostone.Approved
UrapidilMinaprine may increase the hypotensive activities of Urapidil.Investigational
ValsartanMinaprine may increase the hypotensive activities of Valsartan.Approved, Investigational
VareniclineThe risk or severity of adverse effects can be increased when Minaprine is combined with Varenicline.Approved, Investigational
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Minaprine.Approved
VenlafaxineThe metabolism of Minaprine can be decreased when combined with Venlafaxine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Minaprine.Approved
VincamineMinaprine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineMinaprine may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Minaprine.Approved
XipamideMinaprine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineMinaprine may increase the hypotensive activities of Xylometazoline.Approved
ZimelidineMinaprine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Minaprine can be decreased when combined with Ziprasidone.Approved
ZofenoprilMinaprine may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Minaprine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB14943
PubChem Compound
4199
PubChem Substance
46505380
ChemSpider
4054
BindingDB
50074289
ChEBI
51038
ChEMBL
CHEMBL278819
Therapeutic Targets Database
DAP000475
PharmGKB
PA164748351
ATC Codes
N06AX07 — Minaprine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)122 °CPhysProp
water solubility2360 mg/LNot Available
logP2.03HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0701 mg/mLALOGPS
logP2.15ALOGPS
logP2.19ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)19.25ChemAxon
pKa (Strongest Basic)6.28ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area50.28 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity91.17 m3·mol-1ChemAxon
Polarizability33.82 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9843
Caco-2 permeable+0.5161
P-glycoprotein substrateSubstrate0.7122
P-glycoprotein inhibitor IInhibitor0.5884
P-glycoprotein inhibitor IINon-inhibitor0.6707
Renal organic cation transporterNon-inhibitor0.5938
CYP450 2C9 substrateNon-substrate0.8053
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.5794
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.576
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5741
Ames testNon AMES toxic0.7642
CarcinogenicityNon-carcinogens0.7084
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity2.4667 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7911
hERG inhibition (predictor II)Inhibitor0.6866
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpyridazines. These are organic compounds containing a pyridazine ring substituted by a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyridazines and derivatives
Direct Parent
Phenylpyridazines
Alternative Parents
Morpholines / Imidolactams / Benzene and substituted derivatives / Heteroaromatic compounds / Trialkylamines / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenylpyridazine / Monocyclic benzene moiety / Morpholine / Oxazinane / Benzenoid / Imidolactam / Heteroaromatic compound / Tertiary aliphatic amine / Tertiary amine / Azacycle
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
secondary amine, pyridazines, morpholines (CHEBI:51038)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Kan JP, Mouget-Goniot C, Worms P, Biziere K: Effect of the antidepressant minaprine on both forms of monoamine oxidase in the rat. Biochem Pharmacol. 1986 Mar 15;35(6):973-8. [PubMed:3954800]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation...
Gene Name
HTR2B
Uniprot ID
P41595
Uniprot Name
5-hydroxytryptamine receptor 2B
Molecular Weight
54297.41 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Kodama K, Shibata S, Ueki S: Protective effect of minaprine against the abnormal changes of 2-deoxyglucose uptake by rat hippocampal slices induced by hypoxia/hypoglycemia. Jpn J Pharmacol. 1992 Sep;60(1):33-8. [PubMed:1361012]
  4. Muramatsu M, Tamaki-Ohashi J, Usuki C, Araki H, Chaki S, Aihara H: 5-HT2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat brain striatal slices. Eur J Pharmacol. 1988 Aug 9;153(1):89-95. [PubMed:2975224]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Kodama K, Shibata S, Ueki S: Protective effect of minaprine against the abnormal changes of 2-deoxyglucose uptake by rat hippocampal slices induced by hypoxia/hypoglycemia. Jpn J Pharmacol. 1992 Sep;60(1):33-8. [PubMed:1361012]
  2. Nabeshima T, Kawashima K, Kameyama T: Effect of minaprine on cycloheximide-induced amnesia in mice. Eur J Pharmacol. 1989 Oct 10;169(2-3):249-57. [PubMed:2530096]
  3. Muramatsu M, Tamaki-Ohashi J, Usuki C, Araki H, Chaki S, Aihara H: 5-HT2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat brain striatal slices. Eur J Pharmacol. 1988 Aug 9;153(1):89-95. [PubMed:2975224]
  4. Biziere K, Worms P, Kan JP, Mandel P, Garattini S, Roncucci R: Minaprine, a new drug with antidepressant properties. Drugs Exp Clin Res. 1985;11(12):831-40. [PubMed:3836113]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Kodama K, Shibata S, Ueki S: Protective effect of minaprine against the abnormal changes of 2-deoxyglucose uptake by rat hippocampal slices induced by hypoxia/hypoglycemia. Jpn J Pharmacol. 1992 Sep;60(1):33-8. [PubMed:1361012]
  4. Muramatsu M, Tamaki-Ohashi J, Usuki C, Araki H, Chaki S, Aihara H: 5-HT2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat brain striatal slices. Eur J Pharmacol. 1988 Aug 9;153(1):89-95. [PubMed:2975224]
Details
5. Acetylcholinesterase
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine hydrolase activity
Specific Function
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name
ACHE
Uniprot ID
P22303
Uniprot Name
Acetylcholinesterase
Molecular Weight
67795.525 Da
References
  1. Duarte CD, Barreiro EJ, Fraga CA: Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19. [PubMed:18045214]
  2. Contreras JM, Rival YM, Chayer S, Bourguignon JJ, Wermuth CG: Aminopyridazines as acetylcholinesterase inhibitors. J Med Chem. 1999 Feb 25;42(4):730-41. [PubMed:10052979]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Duarte CD, Barreiro EJ, Fraga CA: Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19. [PubMed:18045214]
  2. Worms P, Kan JP, Steinberg R, Terranova JP, Perio A, Biziere K: Cholinomimetic activities of minaprine. Naunyn Schmiedebergs Arch Pharmacol. 1989 Oct;340(4):411-8. [PubMed:2586634]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:43